AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer task (Go/No-Go task)
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: computer task (Go/No-Go task)
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: event-related potentials (ERP) and heart rate measurements
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EEG
Description: event-related potentials (ERP) and heart rate measurements
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pupil size measurements (by using eye tracking)
Study NCT01913912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pupil size measurements (by using eye tracking)
Study NCT03705507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib is a small molecule inhibitor of the MEK protein
Study NCT03705507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
Study NCT03031977 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: visceral mobilization
Study NCT03031977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visceral mobilization
Study NCT02176876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5745
Description: GS-5745 400 mg administered intravenously
Study NCT02176876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-5745
Description: Placebo to match GS-5745 administered intravenously
Study NCT05398562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mycobacterial recombinant allergens 0.1 μg
Description: solution for intradermal injection, 0.1 µg / 0.1 mL
Study NCT05398562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mycobacterial recombinant allergens 0.2 μg
Description: solution for intradermal injection, 0.2 µg / 0.1 mL
Study NCT05398562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for intradermal injection
Study NCT04955522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: Differential diagnosis of spinal myeloma and metastases by radiomics
Study NCT04434794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: autologous mesenchymal stem cells
Study NCT04434794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT04434794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT00989339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twenty-four Hour TPN and Saline Infusion
Description: Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
Study NCT01536847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: 300 ml of liquid food product
Study NCT01536847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 300 mL of liquid food product
Study NCT01536847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 300 ml of liquid food product
Study NCT01710254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson MRI
Description: AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
Study NCT01710254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
Study NCT04602182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: music therapy intervention
Description: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
Study NCT04602182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: music therapy intervention
Description: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
Study NCT01455337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: 400mg tid
Study NCT01455337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 40mg qd
Study NCT00319644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Description: Using catheter to obtain respiratory sample
Study NCT02104700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine/Emtricitabine/Tenofovir
Description: Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
Study NCT03842124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Force gauge
Description: The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
Study NCT01017614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer
Description: * administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained
Study NCT01017614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulphate
Description: 200 mg daily
Study NCT02200445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (aldesleukin).
Description: Description of intervention is covered in Arm, above.
Study NCT00391677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social skills training without attention shaping
Description: Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
Study NCT01909180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revolution CT Scanner
Description: These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational.
Study NCT01672658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Kinetics Balance System
Description: Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
Study NCT01672658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vestibular Rehabilitation
Description: Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
Study NCT04349748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education, and regular HIV and STDs testing prompting service
Description: Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
Study NCT04349748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health status inquiry through app (partner notification)
Description: The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
Study NCT03356418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV exercise group
Description: The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
Study NCT03356418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham WBV exercise group
Description: The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
Study NCT00612547 — intervention group
Intervention type: DRUG
Intervention: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)
Description: Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day
Study NCT04155346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, nutritional optimization, and psychoeducation
Description: Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
Study NCT00435162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 0.25 mg/kg
Description: once daily
Study NCT00435162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 1.0 mg/kg
Description: once daily
Study NCT00435162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 4.0 mg/kg
Description: once daily
Study NCT04284124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae block
Description: Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
Study NCT03354481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arithmetic facts solving
Description: The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
Study NCT04510948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Description: Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care.
Study NCT03885570 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve replacement
Description: Blood transfusion
Study NCT01726153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom-HIM
Description: The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
Study NCT04750694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
Study NCT04750694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
Study NCT03326557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery
Description: Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
Study NCT03898050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcutaneous cardiac pacing
Description: transcutaneous cardiac pacing
Study NCT03807466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic/Interactive vs. Static/Paginated Report
Description: Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
Study NCT03807466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTC Physicians Enrolled vs. Not Enrolled in Reports
Description: Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
Study NCT02944474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Capsule for oral administration containing lucerastat
Study NCT01646645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-pp65 CTLs
Description: Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
Study NCT03362099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Tartrate or bupropion
Description: the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
Study NCT02944474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching lucerastat capsules
Study NCT03274401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zenicor intermittent ECG device
Description: At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
Study NCT03274401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5 day ECG patch
Description: Selection of device for monitoring clinicians' choice
Study NCT02275650 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: nbUVB
Description: 2 SED nbUVB exposure will be given every other week
Study NCT02659306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
Study NCT02263794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bronchial Thermoplasty
Description: Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
Study NCT02263794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Bronchial Thermoplasty
Description: Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
Study NCT00592839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCE-B
Description: 0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
Study NCT00592839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for 0.3 mg and 0.625 mg tablets
Study NCT00592839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 0.3 mg and 0.625 mg tablets
Study NCT04496544 — intervention group
Intervention type: OTHER
Intervention: Retrospective data collection
Description: No intervention; retrospective data collection
Study NCT00075179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (Natrecor)
Description: Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
Study NCT00075179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization
Description: Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
Study NCT01760330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Study NCT01760330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01223989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypocaloric diet balanced + nutrition education + ruled physical activity
Study NCT01223989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet balanced + nutrition education + ruled physical activity
Study NCT03933189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy modalities to treat chronic pain
Study NCT00372125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin SimpleXx
Description: 0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
Study NCT00372125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norditropin SimpleXx
Description: 0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
Study NCT03828357 — intervention group
Intervention type: OTHER
Intervention: Study MRI scan
Description: At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.